Infectious Disease Phase 3 Readout Calendar
Industry-sponsored infectious disease trials with primary completion in the next 12 months or last 12 months.
Data last updated November 12, 2026 · source: ClinicalTrials.gov
What you can answer with this page
A confidence-graded calendar of every industry Phase 3 infectious disease trial reading out in the next 12 months — with a per-row staleness flag so you know which completion dates are still credible.
Recently read-out results are free; the upcoming calendar shows a free preview. See the full cross-area calendar → or the Infectious Disease landscape →
Recently read out & awaiting topline — Infectious Disease
· 3Phase 3 infectious disease trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline. Most recent first.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| Mundipharma Research Limited | Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation Asset: Rezafungin for Injection | Candidemia +9 | Completed | Q1 2026 2026-01-29 | Completed · awaiting
Updated 7mo ago
| NCT04368559 |
| F2G Ltd | Olorofim Aspergillus Infection Study Asset: Olorofim | Invasive Aspergillosis | Completed | Q4 2025 2025-11-18 | Completed · awaiting
Updated 10mo ago
| NCT05101187 |
| ModernaTX, Inc. | Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ���50 Years of Age Asset: mRNA-1083 | COVID-19 +1 | Completed | Q4 2025 2025-11-17 | Completed · awaiting
Updated 11mo ago
| NCT06694389 |
Upcoming infectious disease readouts — next 12 months
· 19Industry Phase 3 infectious disease trials with primary completion ahead, soonest first — confidence-graded by date type and CT.gov staleness.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| Seqirus | A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age Asset: aQIV or aTIV | Influenza, Human | Completed | Q4 2026 2026-11 (est.) | Estimated · aging
Updated 7mo ago
| NCT06087640 |
| LG Chem | A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series Asset: LBVD | Diphtheria +5 | Active Not Recruiting | Q4 2026 2026-11 (est.) | Estimated · stale
Updated 16mo ago
| NCT06947499 |
| Fujian Akeylink Biotechnology Co.,… | To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment Asset: GST-HG141 | Chronic Hepatitis b | Recruiting | Q4 2026 2026-12-01 (est.) | Estimated · aging
Updated 10mo ago
| NCT07090759 |
| Pfizer | A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised Asset: ibuzatrelvir | COVID-19 Infection | Recruiting | Q4 2026 2026-12-06 (est.) | Estimated · aging
Updated 7mo ago
| NCT07013474 |
| Atea Pharmaceuticals, Inc. | C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV Asset: Bemnifosbuvir-Ruzasvir | HEPATITIS C VIRUS CHRONIC INFECTION +3 | Active Not Recruiting | Q4 2026 2026-12 (est.) | Estimated · aging
Updated 7mo ago
| NCT07037277 |
About this calendar
Dates anchor on the ClinicalTrials.gov primary completion date — the only public, structured signal — and are graded by date type (actual vs sponsor-estimated) and how recently the record was updated. Sponsor-estimated dates can slip silently, so treat each as a current target rather than a guarantee. See the full readout calendar for all areas and filters.